Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
axitinib + gemcitabine
- Development stage
- Discontinued
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
**Axitinib + gemcitabine** is a combination therapy comprised of axitinib, an oral small molecule inhibitor of vascular endothelial growth factor receptors 1, 2, and 3 (VEGFR-1, -2, -3), and gemcitabine, a nucleoside analog chemotherapeutic agent that inhibits DNA synthesis. Axitinib targets angiogenesis by blocking VEGFR tyrosine kinases, while gemcitabine acts as an antimetabolite interfering with DNA replication. This combination has been investigated in phase I–III trials for advanced pancreatic cancer. Clinical studies show the combination is generally well tolerated, without significant pharmacokinetic interactions, but does not provide a survival benefit over gemcitabine alone in advanced pancreatic cancer[1][2][3][4][5].
- Other names
- axitinib and gemcitabine
02
Targets
BCR-ABL1 T315I (Bcr-Abl T315I mutant protein)DNA polymerase familyKIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRB (Platelet-derived growth factor receptor beta)RNR (Ribonucleotide reductase)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on axitinib + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on axitinib + gemcitabine.